Device Trial Radar · NCT07772232
Comparison of Holmium Laser Enucleation of the Prostate and Robotic Water Jet Ablation for Benign Prostatic Hyperplasia
Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Aug 3, 2026
Primary completion
Aug 3, 2029
Study completion Aug 3, 2033
Sponsor
- Lead sponsor
- The Methodist Hospital Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 19, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Other
- FDA-regulated device
- Yes
- Who can join
- Male only, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study compares two FDA-approved surgical treatments for benign prostatic hyperplasia (BPH): Holmium Laser Enucleation of the Prostate (HoLEP) with MOSES 2.0 technology and Robotic Water Jet Ablation (RWJA) using the Hydros Robotic System. Men with BPH and prostate volumes between 50 and 180 mL will be randomly assigned to one of the two procedures. The study will measure changes in prostate volume, PSA, urinary flow, and bladder emptying at 12 months, along with safety, sexual function, continence, and healthcare utilization outcomes, which will be followed for up to 5 years after surgery.
Conditions
- Benign Prostate Hypertrophy(BPH)
- Lower Urinary Track Symptoms
Interventions
Device - HoLEP with MOSES 2.0Device
Holmium laser enucleation of the prostate using MOSES 2.0 pulse-modulation technology, performed per institutional standard of care.
RWJA with Hydros Robotic SystemDevice
Device - RWJA (Hydros Robotic System) / Aquablation therapy (often referred to by its commercial name, "Aquablation").
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Prostate VolumeTime frame: Baseline and 12 months post-intervention
- Change in Prostate-Specific Antigen (PSA)Time frame: Baseline and 12 months post-intervention
- Change in Urinary Flow Rate (Qmax)Time frame: Baseline and 12 months post-intervention
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Houston Methodist
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.